WO1994025012A2 - Medicaments for treatment of migraine, epilepsy and feeding disorders - Google Patents
Medicaments for treatment of migraine, epilepsy and feeding disorders Download PDFInfo
- Publication number
- WO1994025012A2 WO1994025012A2 PCT/EP1994/001240 EP9401240W WO9425012A2 WO 1994025012 A2 WO1994025012 A2 WO 1994025012A2 EP 9401240 W EP9401240 W EP 9401240W WO 9425012 A2 WO9425012 A2 WO 9425012A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- 5ht2b
- treatment
- 5ht2b receptor
- Prior art date
Links
- 0 CC1*CCCC1 Chemical compound CC1*CCCC1 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Definitions
- the present invention relates to a novel method of medical treatment, in particular the treatment and prevention of epilepsy and migraine.
- Compounds which have activity as 5HT2C receptor antagonists and activity at the rat fundus serotonin receptor are known in the art. Examples of such compounds are disclosed in WO 93/18028 and WO 92/05170.
- Rat fundus serotonin receptors are presently known as 5HT2B receptors. It has now been found that these 5HT2B receptors are located in regions of the brain, for example in the hippocampus, habenula and hypothalamus regions. It is expected, as a consequence, that compounds which exhibit 5HT2B receptor modulating activity will be of use in the treatment of certain CNS disorders, in particular epilepsy, migraine and feeding disorders. It has also been found that these 5HT2B receptors are located in the gastrointestinal tract. Compounds which exhibit 5HT2B receptor modulating activity are therefore also expected to be of use in the treatment of GI disorders such as irritable bowel syndrome (IBS).
- IBS irritable bowel syndrome
- the present invention therefore provides, in a first aspect, the use of a 5HT2B receptor modulator in the treatment of epilepsy, migraine and feeding disorders.
- a 5HT2B receptor modulator refers to a compound which acts as an agonist or antagonist at the 5HT2B receptor.
- the 5HT2B receptor modulator should preferably be a 5HT2B receptor agonist.
- Preferred 5HT2B receptor agonists include compounds of formula (I) and pharmacuetically acceptable salts thereof:
- R- is an optionally substituted phenyl, thienyl or furyl ring;
- R2 is hydrogen or C ⁇ _6 alkyl;
- R3 and R 4 are independently hydrogen or C ⁇ _6 alkyl;
- R5 and R6 are independently hydrogen or Cj.6 alkyl;
- X is O, S or NH; and
- n and m are independently 1 or 2.
- a particularly preferred 5HT2B receptor agonist of formula (I) is l-(5-(2- thienylmethoxy)-lH-indol-3yl-)propan-2-amine.
- the 5HT2B receptor modulator should preferably be a 5HT2B receptor antagonist.
- Preferred 5HT2B receptor antagonist compounds expected to be useful in the above treatments include those of formula (IA) or pharmaceutically acceptable salts thereof:
- Rj is hydrogen or C ⁇ _6 alkyl
- R2, R3, Rio and Ri 1 are independently hydrogen or C ⁇ . alkyl, or R Q and Ri 1 together form a bond, or R2 and Rio or R3 and Ri 1 together form a C2-6 alkylene chain;
- R4 is hydrogen, C ⁇ _6 alkyl, halogen, NRgRc), OR 2 or COOR12, where Rg, R9 and R 2 are independently hydrogen or C ⁇ g alkyl;
- R5 and Rg are independently hydrogen or C g alkyl
- R7 is hydrogen, C _6 alkyl, C ⁇ . ⁇ alkoxy or halogen; and wherein the urea moiety is attached at the 4-, 5- or 6-position of the indole or indoline ring.
- Preferred compounds of formula (IA) include those exemplified in WO 93/18028 and WO 92/05170, in particular N-(l-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl) urea.
- 5HT2B receptor antagonist compounds include those of formula
- P represents a quinoline or isoquinoline residue, or a 5- or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur;
- R- is hydrogen or C ⁇ _6 alkyl
- R 2 , R3, RIO and R11 are independently hydrogen or C . alkyl, or RlO and R* - together form a bond, or R 2 and -® or R ⁇ and R-- together form a C2-6 alkylene chain;
- R 4 is hydrogen, C g alkyl, halogen, NR 8 R 9 or OR 12 ? where R 8 , R 9 and R 12 are independently hydrogen or C 1. alkyl;
- R5 is hydrogen or Ci.g alkyl
- R is hydrogen, Cj.g alkyl, OR or halogen, where R* 2 is hydrogen or Cj.g alkyl; and n is 2 or 3; and the groups R--* and R 4 are independently hydrogen or C _ - alkyl.
- Preferred compounds of formula (IB) include:
- Certain compounds of formula (I), (IA) and (IB) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of these compounds and the mixtures thereof including racemates. Tautomers of compounds of formula (I), (IA) and (IB) and mixtures thereof will also exhibit 5HT2B activity and therefore also form an aspect of the invention.
- the compounds of the formula (I), (IA) and (IB) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
- acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
- the present invention further provides a method of treatment or prophylaxis of
- CNS disorders such as epilepsy, migraine and feeding disorders, and GI disorders such as IBS, which comprises administering to a host in need thereof an effective amount of a 5HT/2B receptor modulator or a pharmaceutically acceptable salt thereof.
- the invention provides the use of a 5HT2B receptor modulator or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of CNS disorders such as epilepsy, migraine and feeding disorders and GI disorders such as IBS.
- Compounds which exhibit 5HT2B receptor agonist and antagonist activity are also expected to be of use in the treatment and prophylaxis of other CNS disorders.
- Such disorders include anxiety, depression, obsessive compulsive disorders, pain, memory disorders such as Alzheimer's disease, sleep disorders, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
- the 5HT2B receptor agonists and antagonists are usually formulated in a standard pharmaceutical composition.
- Such compositions can be prepared using standard procedures.
- a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
- Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
- the tablets may be coated according to methods well known in normal pharmaceutical practice.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
- fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
- the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
- the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
- the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- the composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
- the dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
- suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may extend for a number of weeks or months.
- Trifluoroacetic anhydride (2.4 ml, 17 mmol) was added to a solution of 3-(2- aminopropyl)-5-benzyloxyindole (prepared by the method of A.S J 7 . Ash and W.R. Wragg, J. Chem. Soc, 1958, 3887; 4.65g, 16.6 mmol) and 4-(N,N-dimethylamino) pyridine (2.07g, 17 mmol) in dry dichloromethane (40 ml) at 0° C. The mixture was stirred for lh at 0° C, then washed twice with water, dried and evaporated.
- the trifluoroacetyl compound (D3, 1.86g, 4.87 mmol) was heated under reflux with potassium carbonate (3.82g, 27.7 mmol) in methanol (90 ml) and water (6 ml) for 6.5h. The mixture was partiaUy evaporated and then partitioned between dichloromethane and water. The aqueous phase was further extracted with dichloromethane. Combined organic phases were washed with brine, dried and evaporated. The crude product (1.39g) was dissolved in ethyl acetate (50 ml) at 0° C and 1M hydrogen chloride/ether (4.9ml, 4.9 mmol) was added slowly. After stirring for 5 min at 0° C, the precipitate was filtered off, washed with ethyl acetate and dried, to give the title compound (1.40g, 89%), m.p. 203- 205° C.
- 5HT2B receptor agonists are expected to be of use in the treatment of epUepsy since l-(5-(2-thienylmethoxy)-lH-indol-3yl-)propan-2-amine (1-100 mgkg"! s.c. 30 min pretest) significantly raised the current at which 50% of mice convulsed in the mouse maximal electroshock seizure (MES) threshold test, carried out as described in Loscher and Schmidt, (1988, EpUepsy Res., 2, 145-181).
- MES mouse maximal electroshock seizure
- 5HT2B receptors are expressed in the stomach fundus of the rat (Foguet et al., 1992, EMBO J. , 11, 3481-3487) where they mediate a contractile response to 5-hydroxytryptamine (5-HT).
- 5-HT 5-hydroxytryptamine
- 5HT2B receptor antagonists are likely to have appetite suppressant actions and be beneficial in the treatment of obesity. These claims are supported by the presence of high levels of 5HT2B receptor mRNA in the hypothalamus (studies carried out at SmithKline Beecham Pharmaceuticals), an area long associated with the control of appetite (Sugrue et al., 1987, Neuropharmacology, 32, 145-182).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A novel method of medical treatment, in particular the treatment and prevention of epilepsy and migraine.
Description
MEDICAMENTS FOR TREATMENT OF MIGRAINE, EPILEPSY AND FEEDING DISORDERS
The present invention relates to a novel method of medical treatment, in particular the treatment and prevention of epilepsy and migraine. Compounds which have activity as 5HT2C receptor antagonists and activity at the rat fundus serotonin receptor are known in the art. Examples of such compounds are disclosed in WO 93/18028 and WO 92/05170.
Rat fundus serotonin receptors are presently known as 5HT2B receptors. It has now been found that these 5HT2B receptors are located in regions of the brain, for example in the hippocampus, habenula and hypothalamus regions. It is expected, as a consequence, that compounds which exhibit 5HT2B receptor modulating activity will be of use in the treatment of certain CNS disorders, in particular epilepsy, migraine and feeding disorders. It has also been found that these 5HT2B receptors are located in the gastrointestinal tract. Compounds which exhibit 5HT2B receptor modulating activity are therefore also expected to be of use in the treatment of GI disorders such as irritable bowel syndrome (IBS).
The present invention therefore provides, in a first aspect, the use of a 5HT2B receptor modulator in the treatment of epilepsy, migraine and feeding disorders. It will be appreciated by those skilled in the art that the term '5HT2B receptor modulator' refers to a compound which acts as an agonist or antagonist at the 5HT2B receptor.
In particular, for the treatment or prophylaxis of epilepsy and feeding disorders such as anorexia nervosa, the 5HT2B receptor modulator should preferably be a 5HT2B receptor agonist. Preferred 5HT2B receptor agonists include compounds of formula (I) and pharmacuetically acceptable salts thereof:
(D
in which
R- is an optionally substituted phenyl, thienyl or furyl ring; R2 is hydrogen or Cχ_6 alkyl; R3 and R4 are independently hydrogen or Cι_6 alkyl; R5 and R6 are independently hydrogen or Cj.6 alkyl;
X is O, S or NH; and n and m are independently 1 or 2.
A particularly preferred 5HT2B receptor agonist of formula (I) is l-(5-(2- thienylmethoxy)-lH-indol-3yl-)propan-2-amine.
For the treatment or prophylaxis of migraine and IBS the 5HT2B receptor modulator should preferably be a 5HT2B receptor antagonist.
Preferred 5HT2B receptor antagonist compounds expected to be useful in the above treatments include those of formula (IA) or pharmaceutically acceptable salts thereof:
(IA) wherein: P represents a quinoline or isoquinoline residue or a 5- or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur,
Rj is hydrogen or Cι_6 alkyl;
R2, R3, Rio and Ri 1 are independently hydrogen or C\. alkyl, or R Q and Ri 1 together form a bond, or R2 and Rio or R3 and Ri 1 together form a C2-6 alkylene chain;
R4 is hydrogen, Cι_6 alkyl, halogen, NRgRc), OR 2 or COOR12, where Rg, R9 and R 2 are independently hydrogen or Cμg alkyl;
R5 and Rg are independently hydrogen or C g alkyl; and
R7 is hydrogen, C _6 alkyl, C\.^ alkoxy or halogen; and wherein the urea moiety is attached at the 4-, 5- or 6-position of the indole or indoline ring.
Preferred compounds of formula (IA) include those exemplified in WO 93/18028 and WO 92/05170, in particular N-(l-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl) urea.
Compounds of formula (IA) can be prepared according to the procedures outlined in WO
93/18028 and WO 92/05170. Further preferred 5HT2B receptor antagonist compounds include those of formula
(IB) or pharmaceutically acceptable salts thereof:
wherein:
P represents a quinoline or isoquinoline residue, or a 5- or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur;
R- is hydrogen or Cι_6 alkyl;
R2, R3, RIO and R11 are independently hydrogen or C . alkyl, or RlO and R* - together form a bond, or R2 and -® or R^ and R-- together form a C2-6 alkylene chain;
R4 is hydrogen, C g alkyl, halogen, NR8R9 or OR12 ? where R8, R9 and R12 are independently hydrogen or C 1. alkyl;
R5 is hydrogen or Ci.g alkyl;
R is hydrogen, Cj.g alkyl, OR or halogen, where R*2 is hydrogen or Cj.g alkyl; and n is 2 or 3; and the groups R--* and R 4 are independently hydrogen or C _ - alkyl. Preferred compounds of formula (IB) include:
5-methyl-l-(3-pyridylcarbamoyl)-2,3-dihydropyrrolo[2,3-f]-indole,
6-methyl-3-(5-quinolinylcarbamoyl)-2,3-dihydro-pyrrolo[3^-e]indole and
N-(5-isoquinolyl)-5-methyl-2,3-dihydropyrrolo[2,3-f] indole-1-carboxamide and pharmaceutically acceptable salts thereof. Compounds of formula (IB) can be prepared according to the procedure outlined in
PCT EP93/02031.
Certain compounds of formula (I), (IA) and (IB) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of these compounds and the mixtures thereof including racemates. Tautomers of compounds of formula (I), (IA) and (IB) and mixtures thereof will also exhibit 5HT2B activity and therefore also form an aspect of the invention.
The compounds of the formula (I), (IA) and (IB) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
The present invention further provides a method of treatment or prophylaxis of
CNS disorders such as epilepsy, migraine and feeding disorders, and GI disorders such as
IBS, which comprises administering to a host in need thereof an effective amount of a 5HT/2B receptor modulator or a pharmaceutically acceptable salt thereof.
In a still further aspect, the invention provides the use of a 5HT2B receptor modulator or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of CNS disorders such as epilepsy, migraine and feeding disorders and GI disorders such as IBS.
Compounds which exhibit 5HT2B receptor agonist and antagonist activity are also expected to be of use in the treatment and prophylaxis of other CNS disorders. Such disorders include anxiety, depression, obsessive compulsive disorders, pain, memory disorders such as Alzheimer's disease, sleep disorders, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
When used in therapy, the 5HT2B receptor agonists and antagonists are usually formulated in a standard pharmaceutical composition. Such compositions can be prepared using standard procedures.
A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and
buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may extend for a number of weeks or months.
Examples
l-(5-(2-thienylmethoxy)-lH-indol-3yl-)propan-2*amine
Description 1
5-Benzyloxy-3-(2-trifluoroacetylamino)propyIindole (Dl)
Trifluoroacetic anhydride (2.4 ml, 17 mmol) was added to a solution of 3-(2- aminopropyl)-5-benzyloxyindole (prepared by the method of A.S J7. Ash and W.R. Wragg, J. Chem. Soc, 1958, 3887; 4.65g, 16.6 mmol) and 4-(N,N-dimethylamino) pyridine (2.07g, 17 mmol) in dry dichloromethane (40 ml) at 0° C. The mixture was stirred for lh at 0° C, then washed twice with water, dried and evaporated. The residue was chiomatographed on silica gel eluted with 1-2% methanol/dichloromethane. Eluted product was recrystaUised from dichloromethane/petrol to give the title compound (3.7 lg, 59%).
NMR (CDC13) δ : 1.23 (3H, d, J = 7), 2.46 (2H, m), 4.38 (1H, m), 5.11 (2H, s), 6.23 (1H, d, J = 7), 6.97 (2H, m), 7.13 (1H, d, J = 2), 7.30 (1H, d, J = 7), 7.38 (3H, m), 7.49 (2H, m), 8.03 (1H, s). MS (El) m/e 376 (M+)
Description 2 5-Hydroxy-3-(2-trifluoroacetyIamino)propylindole (D2)
Benzyloxyindole (Dl, 3.7g, 9.8 mmol) was shaken with 5% palladium on charcoal (0.47g) in ethanol (50 ml) under hydrogen at 50 p.s.i., for 43h. The mixture was filtered through kieselguhr and the filtrate was evaporated. The residue was chiomatographed on silica gel eluted with 2% methanol/dichloromethane. Eluted product was recrystaUised from dichloromethane/methanol to give the title compound (2.22g, 79%)
NMR (CDCI3 CD3OD) δ : 1.22 (3H, d, J = 7), 2.83 (1H, dd, J = 14,7), 3.00 (1H, dd, J = 14,5), 4.34 (1H, m), 6.82 (1H, dd, J = 7,2), 6.99 (1H, s), 7.08 (1H, d, J = 2), 7.22 (1H, d, J = 7), 8.28 (1H, s).
Description 3 5-(2-thienylmethoxy)-3-(2-trifluoroacetyIamino)indole (D3)
A solution of hydroxyindole (D2, 2.22g, 7.76 mmol) in dry dimethylformamide (15 ml) was added to a suspension of sodium hydride (80% in oU, 0.28g, 9.3 mmol) in dimethylformamide (15 ml) at 0° C. After 10 min at 0° C a solution of 2- chloromethylthiophene (1.06g, 8 mmol) in dimethylformamide (10 ml) was added and the mixture was heated for 2h at 90-110° C. The mixture was then evaporated and the residue was dissolved in dichloromethane and washed with dUute hydrochloride acid (pH3), sodium bicarbonate and water. The organic phase was dried and evaporated, and the residue was chromatographed on silica gel with 1-2% methanol/dichloromethane, to give the title compound (1.87g, 63%).
NMR (CDC13) δ : 1.26 (3H, d, J = 7), 2.98 (2H, m), 4.38 (IH, m), 5.28 (2H, s), 6.22 (IH, d, J = 7), 6.95 (IH, dd, J = 7,2), 7.00 (2H, m), 7.13 (IH, d, J = 4), 7.18 (IH, d, J = 2), 7.29 (IH, d, J = 7), 7.34 (IH, d, J = 6), 8.05 (IH, s).
MS (El) m/e 382 (M+)
Example 1 l-[5-(2-Thienylmethoxy)-lH-indol-3-yl]propan-2-amine hydrochloride (El)
The trifluoroacetyl compound (D3, 1.86g, 4.87 mmol) was heated under reflux with potassium carbonate (3.82g, 27.7 mmol) in methanol (90 ml) and water (6 ml) for 6.5h. The mixture was partiaUy evaporated and then partitioned between dichloromethane and water. The aqueous phase was further extracted with dichloromethane. Combined organic phases were washed with brine, dried and evaporated. The crude product (1.39g) was dissolved in ethyl acetate (50 ml) at 0° C and 1M hydrogen chloride/ether (4.9ml, 4.9 mmol) was added slowly. After stirring for 5 min at 0° C, the precipitate was filtered off, washed with ethyl acetate and dried, to give the title compound (1.40g, 89%), m.p. 203- 205° C.
NMR (dg-DMSO) δ : 1.19 (3H, d, J = 7), 2.80 (IH, dd, J = 14, 7), 3.09 (IH, dd, J = 14, 5), 5.31 (2H, s), 6.80 (IH, dd, J = 7,2), 7.03 (IH, dd, J = 6, 4), 7.20-7.31 (4H, m), 7.54 (IH, d, J = 6), 8.01 (IH, s). MS (Cl) m/e 287 (MH+)
Pharmacological Data
Epilepsy
5HT2B receptor agonists are expected to be of use in the treatment of epUepsy since l-(5-(2-thienylmethoxy)-lH-indol-3yl-)propan-2-amine (1-100 mgkg"! s.c. 30 min pretest) significantly raised the current at which 50% of mice convulsed in the mouse maximal electroshock seizure (MES) threshold test, carried out as described in Loscher and Schmidt, (1988, EpUepsy Res., 2, 145-181). This is consistent with the presence of 5HT2B receptor mRNA in the rat hippocampus, an area which can mediate convulsions (McNamara et al., 1993, in Epilepsy, models, mechanisms and concepts, Ed, Schwartzkroin, Cambridge University Press, pp 27-47).
IBS
5HT2B receptors are expressed in the stomach fundus of the rat (Foguet et al., 1992, EMBO J. , 11, 3481-3487) where they mediate a contractile response to 5-hydroxytryptamine (5-HT). l-(5-(2-t enylmethoxy)-lH-indol-3yl-)propan-2-amine also causes contraction of rat stomach fundus and is a selective agonist at 5HT2B receptors in this preparation (pEC50[95% Confidence limits] = 8.47 [8.04 - 8.90]).
In bUateraUy vagotomised spinal rats, l-(5-(2-thienylmethoxy)-lH-indol-3yl-)propan-2- amine (1-100 μgkg'l i.v.) evokes a dose-dependant and significant increase in gastric motUity in vivo causing a significant increase in intragastric pressure (for methodology see Dhasmana et al., 1992, Eur. J. Pharmacol., 213, 293 299). This action is blocked by selective 5HT2B receptor antagonists such as those disclosed in Patent (WO 93/18028) and supports a use for 5HT2B receptor modulators in disorders of gastric motUity. Such a use is further supported by the observation that the 5HT2B receptor antagonist 6-methyl- 3-(5-quinoUnylcaιbamoyl)-2,3-dihydro-pyιrolo[3,2-e]indole (10 - 10000 μgkg"1 s.c.) significantly reduced 5-hydroxytryptophan-induced increase in faecal peUet output in the conscious mouse (for methods see Banner et al., 1993, Br. J. Pharmacol., 110, 17P).
Feeding Disorders
When given at doses between 1 and 100 mgkg'l s.c. 30 min pretest, or at doses between 1 and 30μg c.v. 4 min pretest, l-(5-(2-thienylmethoxy)-lH-indol-3yl-)propan-2-amine
significantly increases feeding behaviour and food intake in freely-feeding, sated rats. The methodology used in these studies was as described in Kennett et al., (1992, Eur. J. Pharmacol., 141, 429-435). Thus 5HT2B receptor agonists are expected to be of therapeutic use in the treatment of feeding disorders such as anorexia nervosa and bulimia. Furthermore, selective 5HT2B receptor antagonists are likely to have appetite suppressant actions and be beneficial in the treatment of obesity. These claims are supported by the presence of high levels of 5HT2B receptor mRNA in the hypothalamus (studies carried out at SmithKline Beecham Pharmaceuticals), an area long associated with the control of appetite (Sugrue et al., 1987, Neuropharmacology, 32, 145-182).
Migraine
l-(5-(2-thienylmethoxy)-lH-indol-3yl-)propan-2-amine (mean pEC50 [95% CL] 7.9 [7.7
- 8.1] with an intrinsic activity (IA)of 0.84 + 0.04, n=9) and 5-HT (mean pEC50 [95% CL] 8.2 [8.0 - 8.3] IA 1.0,n=9) evokes endothehum-dependant relaxation of isolated rat jugular vein via activation of 5HT2B receptors with a maximal relaxation to 5HT of 73.8 + 4.6%, n=9 (for basic methods see Bodelsson et al., 1993, J. Phaπn. Exp. Ther, 264, 709
- 716). EndotheUum-dependant 5HT-induced relaxation of isolated smooth muscle preparations has been suggested to be due to release of endotheUum derived nitric oxide (Martin et al., 1992, Br. J. Phaπnacol, 105, 643 - 652). Local application of 5HT to cerebral arterioles in vivo induces dUatation which is antagonised by inhibitors of nitric oxide synthase (Parsons et al., 1992, In; 5-Hydroxytryptamine mechanisms in primary headaches, Ed. Olesen & Saxena, Raven Press, NY, ppl57 - 162) suggesting the presence of cerebrovascular 5HT2B receptors. Furthermore the pharmacological character of the receptor mediating the dUation is that expected for 5HT2B- Agonist potency order α- methyl 5HT = 5HT > 5CT. (Pryke et al., Brit. J. Pharmacol. 1989, 98, 685p). DUatation of cerebral arteries has been shown to induce a migraine-like headache (Nichols et al., 1991, Stroke, 21, 555 - 559). 5H 2B receptor modulators are therefore expected to be effective in the treatment or prophylaxis of migraine.
Claims
1. Use of a 5HT2B receptor antagonist for the treatment of migraine.
2. Use according to claim 1 in which the 5HT2B receptor antagonist is a compound of formula (IA) or a phaimaceuticaUy acceptable salt thereof:
(IA)
wherein:
P represents a quinoline or isoquinoline residue or a 5- or 6-membered aromatic heterocycUc ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur,
R is hydrogen or Ci.g alkyl;
R2, R3, Rio and R are independently hydrogen or C\. alkyl, or R Q and Ri together form a bond, or R2 and RIQ or R3 and R together form a C2-6 alkylene chain;
R4 is hydrogen, Ci.g alkyl, halogen, NRgR , OR12 or COOR12, where Rg, R9 and R12 are independently hydrogen or Cι_g alkyl;
R5 and Rg are independendy hydrogen or C _g alkyl; and
R7 is hydrogen, Ci.g alkyl, C g alkoxy or halogen; and wherein the urea moiety is attached at the 4-, 5- or 6-position of the indole or indoline ring.
3. Use according to claim 1 in which the 5HT2B receptor antagonist is a compound of formula (IB) or a phaimaceuticaUy acceptable salt thereof:
R- is hydrogen or Cι_g alkyl;
R2, R3, R-Q and R^ are independently hydrogen or Cι_6 alkyl, or R-® and R^ together form a bond, or R2 and R--* or R^ and R-- toge±er form a C2.6 alkylene chain;
R4 is hydrogen, Cι_6 alkyl, halogen, NR8R9 or OR12 > where R8, R9 and R12 are independently hydrogen or C\. alkyl; R5 is hydrogen or C\. alkyl;
R? is hydrogen, C\. alkyl, OR*2 or halogen, where R*2 is hydrogen or Cι_6 alkyl; and n is 2 or 3; and the groups R--* and R*4 are independentiy hydrogen or C .g alkyl.
4. Use according to claim 3 in which the compound of formula (IB) is 5-methyl- 1 -(3-pyridylca_rbamoyl)-2,3-dihydropyrrolo[2,3-f]indole, 6-methyl-3-(5-quinoUnylcarbamoyl)-2,3-dihydro-pyπolo[3,2-e]indole, or N-(5-isoquinolyl)-5-methyl-2,3-dihydropyrrolo[2,3-f] indole-1-carboxamide or phaimaceuticaUy acceptable salts thereof.
5. Use of a 5HT2B receptor agonist in the treatment of epUepsy and feeding disorders.
6. Use according to claim 5 in which the 5HT2B receptor agonist is a compound of formula (I) and pharmacueticaUy acceptable salts thereof:
(I) in which
R1 is an optionaUy substituted phenyl, thienyl or fuiyl ring;
R2 is hydrogen or C\. alkyl;
R3 and R4 are independently hydrogen or C . alkyl;
R5 and R~* are independently hydrogen or C\. alkyl; X is O, S or NH; and n and m are independently 1 or 2.
7. Use according to claim 6 in which the 5HT2B receptor agonist is l-(5-(2- thienylmethoxy)-lH-indol-3yl-)propan-2-amine or a pharmacueticaUy acceptable salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU65697/94A AU6569794A (en) | 1993-04-28 | 1994-04-20 | Medicaments for treatment of migraine, epilepsy and feeding disorders |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939308802A GB9308802D0 (en) | 1993-04-28 | 1993-04-28 | Treatment |
| GB9308802.9 | 1993-04-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994025012A2 true WO1994025012A2 (en) | 1994-11-10 |
| WO1994025012A3 WO1994025012A3 (en) | 1994-12-22 |
Family
ID=10734635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1994/001240 WO1994025012A2 (en) | 1993-04-28 | 1994-04-20 | Medicaments for treatment of migraine, epilepsy and feeding disorders |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU6569794A (en) |
| GB (1) | GB9308802D0 (en) |
| WO (1) | WO1994025012A2 (en) |
| ZA (1) | ZA942809B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677321A (en) * | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
| WO1998031354A2 (en) * | 1997-01-17 | 1998-07-23 | Smithkline Beecham Plc | Use of 5-ht2b agonists or potentiators in cns disorders |
| US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
| US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110587B2 (en) | 2002-02-11 | 2012-02-07 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992005170A1 (en) * | 1990-09-13 | 1992-04-02 | Beecham Group Plc | Indole ureas as 5 ht receptor antagonist |
| WO1993018026A1 (en) * | 1992-03-04 | 1993-09-16 | Beecham Group Plc | Indole ureas as 5-ht1c receptor antogonists |
| WO1993018028A1 (en) * | 1992-03-12 | 1993-09-16 | Smithkline Beecham Plc | Indole derivatives as 5ht1c antagonists |
-
1993
- 1993-04-28 GB GB939308802A patent/GB9308802D0/en active Pending
-
1994
- 1994-04-20 WO PCT/EP1994/001240 patent/WO1994025012A2/en active Application Filing
- 1994-04-20 AU AU65697/94A patent/AU6569794A/en not_active Abandoned
- 1994-04-22 ZA ZA942809A patent/ZA942809B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992005170A1 (en) * | 1990-09-13 | 1992-04-02 | Beecham Group Plc | Indole ureas as 5 ht receptor antagonist |
| WO1993018026A1 (en) * | 1992-03-04 | 1993-09-16 | Beecham Group Plc | Indole ureas as 5-ht1c receptor antogonists |
| WO1993018028A1 (en) * | 1992-03-12 | 1993-09-16 | Smithkline Beecham Plc | Indole derivatives as 5ht1c antagonists |
Non-Patent Citations (7)
| Title |
|---|
| BR.J.PHARMACOL., vol.111, no.3, March 1994 pages 797 - 802 G.A.KENNETT ET AL. 'In vivo properties of SB 200646A, a 5-HT 2c/2b receptor antagonist' * |
| CAN.J.HOSP.PHARM., vol.45, no.5, October 1992 pages 183 - 186 Z.AUSTIN 'The Serotonin System, Part I: Clinical Significance' * |
| FEBS LETT., vol.342, no.1, 28 March 1994 pages 85 - 90 K.SCHMUCK ET AL. 'Cloning and functional characterization of the human 5-HT 2B serotonin receptor' * |
| J.MED.CHEM., vol.29, no.11, November 1986 pages 2415 - 2418 P-FLUDZINSKI ET AL. '2,3-Dialkyl(dimethylamino)indoles: Interaction with 5HT1, 5HT2, and Rat Stomach Fundal Serotonin Receptors' * |
| J.MED.CHEM., vol.36, no.8, 16 April 1993 pages 1104 - 1107 I.T.FORBES ET AL. 'N-(1-Methyl-5-indolyl)- N'-(3-pyridyl)urea Hydrochloride: The First Selective 5-HT1c receptor Antagonist' * |
| LIFE SCI., vol.54, no.10, 1994 pages 641 - 644 H.O.KALKMAN 'IS MIGRAINE PROPHYLACTIC ACTIVITY CAUSED BY 5-HT 2B OR 5-HT 2C RECEPTOR BLOCKADE ?' * |
| PHARMACOL.TOXICOL., vol.72, no.SUP2, 1993 H.O.KALKMAN ET AL. 'MIGRAINE PROPHYLAXIS BY 5HT2B RECEPTOR BLOCKADE?' * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723741B2 (en) | 1996-02-29 | 2004-04-20 | Synaptic Pharmaceutical Corporation | Benzimidazoles and benzothiazoles and uses thereof |
| US6303643B1 (en) | 1996-02-29 | 2001-10-16 | Synaptic Pharmaceutical Corporation | Substituted indoles and uses thereof |
| US6040451A (en) * | 1996-02-29 | 2000-03-21 | Synaptic Pharmaceutical Corporation | Substituted indoles and uses thereof |
| US5948804A (en) * | 1996-02-29 | 1999-09-07 | Synaptic Pharmaceutical Corporation | Substituted indoles and uses thereof |
| US5677321A (en) * | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
| US6159998A (en) * | 1996-02-29 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Substituted indoles and uses thereof |
| US6498177B2 (en) | 1996-02-29 | 2002-12-24 | Synaptic Pharmaceutical Corporation | Indole and benzothiazole derivatives |
| WO1998031354A2 (en) * | 1997-01-17 | 1998-07-23 | Smithkline Beecham Plc | Use of 5-ht2b agonists or potentiators in cns disorders |
| WO1998031354A3 (en) * | 1997-01-17 | 1998-09-17 | Smithkline Beecham Plc | Use of 5-HT2b agonists or potentiators in CNS disorders |
| US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US8841330B2 (en) | 1999-01-13 | 2014-09-23 | Bayer Healthcare Llc | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
| US8242147B2 (en) | 2002-02-11 | 2012-08-14 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
| US8618141B2 (en) | 2002-02-11 | 2013-12-31 | Bayer Healthcare Llc | Aryl ureas with angiogenesis inhibiting activity |
| US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA942809B (en) | 1995-10-23 |
| AU6569794A (en) | 1994-11-21 |
| WO1994025012A3 (en) | 1994-12-22 |
| GB9308802D0 (en) | 1993-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1448560B1 (en) | 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS | |
| KR950010163B1 (en) | Novel indole derivatives | |
| RU2191176C2 (en) | Tricyclic derivatives of pyrazole, pharmaceutical composition | |
| JP2001526643A (en) | Bicyclic aryl or heterocyclic rings, including compounds having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity | |
| JP3327473B2 (en) | Indole derivatives | |
| JP3328936B2 (en) | Indole and indoline derivatives for 5HT1D receptor antagonists | |
| JP2004517072A (en) | Compounds useful in treating CNS disorders | |
| EP1341759A2 (en) | 3-substituted oxindole beta 3 agonists | |
| JPH07504429A (en) | Indole derivatives as 5HT↓1c antagonists | |
| JP2010521473A (en) | Compounds as angiogenesis inhibitors | |
| JP2005527463A (en) | 3-Arylsulfonyl-7-piperazinyl-indole, -benzofuran and -benzothiophene with 5-HT6 receptor affinity for treating CNS diseases | |
| JP2004532240A (en) | Benzo [D] azepine derivatives as 5-HT6 receptor antagonists | |
| EP1448561A1 (en) | Beta 3 adrenergic agonists | |
| JP2001524116A (en) | Indole derivative having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity | |
| WO2003066632A1 (en) | Sulphonyl compounds with 5 -ht6 receptor affinity | |
| UA45325C2 (en) | BENZONITRILES AND BENZOFLUORIDES, THE METHOD OF OBTAINING THEM, THE PHARMACEUTICAL COMPOSITION, THE METHOD OF OBTAINING IT, THE METHOD OF CONTROLLING THE DISEASE | |
| JPH07291969A (en) | 3-indolylpiperidine | |
| JP2001512727A (en) | Bicyclic compounds as ligands for the 5HT-1 receptor | |
| WO1994025012A2 (en) | Medicaments for treatment of migraine, epilepsy and feeding disorders | |
| JPH08502273A (en) | 5-HT 4) Heterocyclic ester or amide for receptor antagonist | |
| US6313145B1 (en) | Indoline derivatives useful as 5-HT-2C receptor antagonists | |
| RU2165420C2 (en) | 1,2,5-thiadiazole derivatives of indolylalkyl-pyrimidinyl-piperazines and pharmaceutical composition based on these compounds | |
| JP2001506995A (en) | N-piperazin-1-ylphenyl-benzamide derivatives | |
| KR20050119673A (en) | Chromenone indoles | |
| EP0703914A1 (en) | 8-amino-7-chloro-1,4-benzodioxan-5-carboxylic acid, -1-butyl-4-piperidinyl ester as a 5-ht4-receptor antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |